AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

Tariffs are "certainly not material long term," Soriot said, adding that AstraZeneca will rely on the existing global network to shift manufacturing as needed.

AstraZeneca AZN -1.14% plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology companies, at a time Chinese ...

Covington & Burling's London operation has advised pharmaceuticals giant AstraZeneca on its $1 billion acquisition of EsoBiotec, a Belgian biotechnology company specialising in vivo cell therapies.

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform.

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said ...

Having languished down the leaderboard in the past, AstraZeneca vaulted over rivals to take the second spot on a reputation ranking.

AstraZeneca ADRs jumped to a record high Tuesday after the company announced plans for a “new era of growth” with 75% revenue growth by 2030.

AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand.

(Reuters) -AstraZeneca said on Tuesday it will invest $300 million in a facility in Rockville, Maryland, for discovery and development of cell therapies.

AstraZeneca will pay $425 million to settle lawsuits on behalf of consumers who suffered kidney injuries while using its heartburn medications Nexium and Prilosec.